Magenta therapeutics reports third quarter financial results and program highlights

Cambridge, mass.--(business wire)--magenta therapeutics, inc. (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the third quarter ended september 30, 2021, and recent program highlights. “we are pleased with our recent execution across the portfolio as we look to continue to allocate our capital efficiently to our value-creating opportunities,” sai
DNTH Ratings Summary
DNTH Quant Ranking